Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
CycloME
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==CycloME part Aβ== The first cyclophosphamide trial was a single centre, unblinded study with 40 patients with mild/moderate to [[Severe and very severe ME|severe ME]] but not very severe ME.<ref name="PhaseII" /> Some of the participants were previously treated with [[Rituximab]].<ref name="PhaseII"/> The Department of Oncology at Haukeland University Hospital was responsible for assessing which patients to include the trial, as well as administering the treatments. The Norwegian Radium Hospital, Oslo, took part in the trial as a treatment centre, administering treatments to a small group of patients from the Oslo area.<ref name="PhaseII" /> The [[Canadian Consensus Criteria]] was used in selecting participants.<ref name="PhaseII" /> All participants received six intravenous treatments of [[cyclophosphamide]], each treatment four weeks apart. The participants was followed-up for one year. Each was given complete physical examinations and testing before and after treatment, and submitted regular reports on any changes in symptoms and physical function.<ref name="Rekeland2020" /> The physical function testing included a measurement of activity via a Sensewear armband (a wearable device that measures physical activity and total energy expenditure expressed as Kcal), two-day Cardiopulmonary exercise tests for those who are able, and self-reporting fatigue scores. Adverse effects were tested for with physical examinations and laboratory tests.<ref name="Rekeland2020" /> Side effects were expected to be minimal, because similar dosages have already been used in breast cancer and lymphoma trials, although some serious adverse responses did occur.<ref name="PhaseII" /><ref name="Rekeland2020" /> Study results were published in 2020.<ref name="Rekeland2020" /> Data analysis included comparing the group who received [[rituximab]] prior to those who did not.<ref name="Rekeland2020" />
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs